Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Gossamer Bio Analyst Ratings and Price Targets | NASDAQ:GOSS | Benzinga
Gossamer Bio Inc has a consensus price target of $6.96 based on the ratings of 14 analysts. The high is $15 issued by Piper Sandler on March 27, 2024. The low is $1.5 issued by Barclays on March 21, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, HC Wainwright & Co., and Wedbush on April 17, 2025, March 18, 2025, and March 14, 2025, respectively. With an average price target of $7 between Goldman Sachs, HC Wainwright & Co., and Wedbush, there's an implied 516.74% upside for Gossamer Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
HC Wainwright & Co.
Wedbush
Oppenheimer
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Gossamer Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | 516.74% | Goldman Sachs | Paul Choi61% | $8 → $7 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2025 | Buy Now | 252.42% | Wedbush | Laura Chico31% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2025 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 252.42% | Wedbush | Laura Chico31% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 06/25/2024 | Buy Now | 692.95% | Oppenheimer | Andreas Argyrides69% | → $9 | Initiates | → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 604.85% | Goldman Sachs | Paul Choi61% | $8 → $8 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $20 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 252.42% | Wedbush | Laura Chico31% | $4 → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 05/06/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 252.42% | Wedbush | Laura Chico31% | → $4 | Assumes | → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 1221.59% | Piper Sandler | Yasmeen Rahimi57% | → $15 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 428.63% | Wedbush | Andreas Argyrides69% | $6 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 604.85% | Goldman Sachs | Paul Choi61% | $9 → $8 | Maintains | Buy | Get Alert |
| 01/08/2024 | Buy Now | 781.06% | HC Wainwright & Co. | Patrick Trucchio38% | $5 → $10 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 428.63% | Wedbush | Andreas Argyrides75% | $6 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 428.63% | Wedbush | Andreas Argyrides69% | $5 → $6 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 340.53% | Wedbush | Andreas Argyrides69% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 340.53% | HC Wainwright & Co. | Patrick Trucchio38% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | 340.53% | Wedbush | Andreas Argyrides69% | $7 → $5 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 340.53% | HC Wainwright & Co. | Patrick Trucchio38% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 516.74% | Wedbush | Andreas Argyrides69% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 340.53% | HC Wainwright & Co. | Patrick Trucchio38% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2023 | Buy Now | 32.16% | Barclays | Carter Gould59% | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 03/07/2023 | Buy Now | 340.53% | Raymond James | Timur Ivannikov63% | → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Initiates | → Neutral | Get Alert |
| 12/08/2022 | Buy Now | 340.53% | HC Wainwright & Co. | Patrick Trucchio38% | $25 → $5 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 781.06% | Goldman Sachs | Paul Choi61% | $22 → $10 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 604.85% | UBS | Eliana Merle43% | $19 → $8 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | — | JP Morgan | Brian Cheng46% | — | Downgrade | Neutral → Underweight | Get Alert |
| 12/07/2022 | Buy Now | 76.21% | Barclays | Carter Gould59% | $18 → $2 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/07/2022 | Buy Now | 164.32% | SMBC Nikko | David Hoang37% | → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 12/07/2022 | Buy Now | 340.53% | Raymond James | Steven Seedhouse65% | $15 → $5 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 781.06% | SVB Leerink | Joseph Schwartz37% | $15 → $10 | Maintains | Outperform | Get Alert |
| 11/17/2022 | Buy Now | 1221.59% | Raymond James | Steven Seedhouse65% | $18 → $15 | Maintains | Outperform | Get Alert |
| 10/20/2022 | Buy Now | 1838.33% | Goldman Sachs | Paul Choi61% | → $22 | Initiates | → Buy | Get Alert |
| 09/21/2022 | Buy Now | 1397.8% | JP Morgan | Brian Cheng46% | → $17 | Initiates | → Neutral | Get Alert |
| 09/19/2022 | Buy Now | 2014.54% | Wedbush | Andreas Argyrides69% | → $24 | Initiates | → Outperform | Get Alert |
| 08/18/2022 | Buy Now | 1485.9% | Barclays | Carter Gould59% | $12 → $18 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 1485.9% | Raymond James | Steven Seedhouse65% | $14 → $18 | Maintains | Outperform | Get Alert |
| 07/14/2022 | Buy Now | 1133.48% | Raymond James | Steven Seedhouse65% | $10 → $14 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | 1221.59% | SVB Leerink | Joseph Schwartz37% | $16 → $15 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Gossamer Bio (GOSS) stock?
The latest price target for Gossamer Bio (NASDAQ:GOSS) was reported by Goldman Sachs on April 17, 2025. The analyst firm set a price target for $7.00 expecting GOSS to rise to within 12 months (a possible 516.74% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gossamer Bio (GOSS)?
The latest analyst rating for Gossamer Bio (NASDAQ:GOSS) was provided by Goldman Sachs, and Gossamer Bio maintained their buy rating.
When was the last upgrade for Gossamer Bio (GOSS)?
There is no last upgrade for Gossamer Bio
When was the last downgrade for Gossamer Bio (GOSS)?
The last downgrade for Gossamer Bio Inc happened on March 7, 2023 when Raymond James changed their price target from N/A to $5 for Gossamer Bio Inc.
When is the next analyst rating going to be posted or updated for Gossamer Bio (GOSS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Gossamer Bio (GOSS) correct?
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a maintained with a price target of $8.00 to $7.00. The current price Gossamer Bio (GOSS) is trading at is $1.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
